{"name":"Atom Therapeutics Co., Ltd","slug":"atom-therapeutics-co-ltd","ticker":"","exchange":"","domain":"atom.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":4,"colorKey":"oncology","drugs":[{"name":"ABP-671 plus allopurinol","genericName":"ABP-671 plus allopurinol","slug":"abp-671-plus-allopurinol","indication":"Other","status":"phase_1"},{"name":"ABP-745","genericName":"ABP-745","slug":"abp-745","indication":"Other","status":"phase_1"},{"name":"ABP-745 Dose B","genericName":"ABP-745 Dose B","slug":"abp-745-dose-b","indication":"Other","status":"phase_2"},{"name":"ABP-745 Dose C","genericName":"ABP-745 Dose C","slug":"abp-745-dose-c","indication":"Other","status":"phase_2"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"ABP-745 Dose A","genericName":"ABP-745 Dose A","slug":"abp-745-dose-a","indication":"Non-small cell lung cancer, metastatic or locally advanced, PD-L1 positive","status":"phase_2"}]}],"pipeline":[{"name":"ABP-671 plus allopurinol","genericName":"ABP-671 plus allopurinol","slug":"abp-671-plus-allopurinol","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABP-745 Dose A","genericName":"ABP-745 Dose A","slug":"abp-745-dose-a","phase":"phase_2","mechanism":"ABP-745 is a bispecific antibody that targets and blocks PD-1 and CTLA-4 receptors.","indications":["Non-small cell lung cancer, metastatic or locally advanced, PD-L1 positive","Head and neck squamous cell carcinoma, metastatic"],"catalyst":""},{"name":"ABP-745","genericName":"ABP-745","slug":"abp-745","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABP-745 Dose B","genericName":"ABP-745 Dose B","slug":"abp-745-dose-b","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ABP-745 Dose C","genericName":"ABP-745 Dose C","slug":"abp-745-dose-c","phase":"phase_2","mechanism":"ABP-745 is a bispecific antibody that simultaneously engages two distinct molecular targets to modulate immune or disease-related pathways.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxQdm5HRnRVcUYzWG44R1MtbTJaYl9jeE5qakQ1blNrcUcyQnhqUi1RM1NqbDE0NVRKQnJtMnFfNWNHbFdYSGY5TWdRVW42WEpGeF9TRklEZTN6cmszVl8yTWdLaGdKaHlVcVNjVzNEUVFmX3puS19yR2EyWUg5anJ3eEhUOUJ3N19Rd3BrRHBibVJ4aXBMZkhiYVZMY3FUWndIYktCY0Fn?oc=5","date":"2026-03-21","type":"pipeline","source":"富途牛牛","summary":"IPO News | Xinyuansu Pharmaceuticals Re-Files for Listing on the Hong Kong Stock Exchange - 富途牛牛","headline":"IPO News | Xinyuansu Pharmaceuticals Re-Files for Listing on the Hong Kong Stock Exchange - 富途牛牛","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwJBVV95cUxPN3lXNW10bWY0M1ZVYk1rc2Vpbm5fY0RpeGRHeTNvOE9kcUV5MHUxVnJyNkR1TVNVNHpmdE9lYzlUWV9KYjFfamNRSWhKcHdWcFdSX1RzTG01N2lnWUV3X3R4dmhsM21ORHFHN2VEVGRxbC1GaTZtcmdLNlQ3c043WG8ybkl5NzVNUEhYSFdqLXE5U2ZNTzVZQzF1SUVNUmQ2alRROFNjaDdZMVUxWG1jQ2VLQ2hraWI2eHZQRk5EOTIweDBrYUJLakF1MGV5THdRWHpkeGxuWG9Db002alZjYW03ZGk1MW0zVTlaT3ZVNGNmV0UyZTdXZU5SekhYVld0c3huWUJHeTZtVkxidUVGNC1nRQ?oc=5","date":"2026-02-24","type":"trial","source":"Newswire Canada","summary":"AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-BetaBart (RV-01) - Newswire Canada","headline":"AtomVie Global Radiopharma Supplies First Patient Dose in Radiopharm Theranostics' Phase 1/2a Clinical Study of 177Lu-Be","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1AFBVV95cUxOZDBRbE9UNGtVbzE3MUNCMW5hWElpLURILXBqcmR6dU14OTZ3NTJwREhZQ2tmd3BFa3pDY0dNdmlqdHZGbXhXNjhHeXh2UVl5SmZYNlllaDQyTGtNbDRMOEtTUTJ0bmVUTHpyWEJEV2MxMmhHQ1JCTGg0bHFVZms3WFlDWDk3MnlGN3ExTG1hcUJrUnVFRFYxTDR4UElpUVFPRXhtbFNhaUZQZExuREhHMnZoWjZYR3k4MUtBUW5lR3pnZy1HSXNSWFk3VkF4QXFpenNWSg?oc=5","date":"2025-12-18","type":"regulatory","source":"BioPharma APAC","summary":"Atom Therapeutics Secures FDA Approval To Advance Phase II Trial Of ABP 745 In Atherosclerosis - BioPharma APAC","headline":"Atom Therapeutics Secures FDA Approval To Advance Phase II Trial Of ABP 745 In Atherosclerosis","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijwJBVV95cUxONnhjanZWSWlKMVg1QzdZNHRlZUtRTUJPMjNHalZhSEl2c3FqS3RuNEthUUMwYVBtSGh1S19ON0lLbWxGdG0wdmhIdGNYQ29wT191a0EtdVpOWFFxaGluRUNVa3VTaEctakZLeW5Rc2NxcXFlcHVZaThxZzZWUW9ZX0o4cjdSWnJVTG03QjYtTVR6bGJkTFJ0TGxjVF90QWdZdlY2SU9kY0VtYmdLWDZURTBpeGpvc2xITWtHYVEtZGRTU0NSZXdKZDhMa1ZkYUtVaHUwZDRYalB5N0YzZTVMMVdoaXlGYUlFMVRfMUNIVU5QN29rd1pxWXY3RTN4ekVxbGM5U2NVLUo5VEQyYU9Z?oc=5","date":"2025-12-18","type":"pipeline","source":"Newswire Canada","summary":"AtomVie Global Radiopharma Secures a Supply Agreement with Ionetix Corporation to Accelerate Ac-225 Radiotherapeutics Development - Newswire Canada","headline":"AtomVie Global Radiopharma Secures a Supply Agreement with Ionetix Corporation to Accelerate Ac-225 Radiotherapeutics De","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNUGpmMXViT0VibGNET2JnM3V6YXNEcnJlY2xwR21zTHpXT2l5dWpJeEE1SEdSeVdSeWRCSG56YmtrSnhIZnNnTF9taVpGMjhlTHlzN1ZGa1VEVExSNno1anNPakpKWG1LbVJKcDZoMTJSOU9CbVZ2czFoYk5KTFlKbU1HZ1o5aEFzZGxyblU1UGx3STlhUDZja3JIQU9CWmphZkViQjdYY1lSTklLMEhz?oc=5","date":"2025-12-03","type":"pipeline","source":"ontario.ca","summary":"Ontario Welcomes $138 Million Investment in the Life Sciences Sector - ontario.ca","headline":"Ontario Welcomes $138 Million Investment in the Life Sciences Sector","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-11-12","type":"trial","source":"PR Newswire","summary":"AtomVie Global Radiopharma Supplies the First Patient Dose of 225Ac-SSO110 for Ariceum Therapeutics' Phase 1/2 SANTANA-225 Clinical Trial in Extensive-Stage Small Cell Lung Cancer and Merkel Cell Carc","headline":"AtomVie Global Radiopharma Supplies the First Patient Dose of 225Ac-SSO110 for Ariceum Therapeutics' Phase 1/2 SANTANA-2","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxNV0QzOGowYW1zOGJnbTVnWjJqUm9aR2Jpc1JiRWVxUzd1N0s2cjhyRjAzam8zcENEczdrRFBXeVZVMU9kbFBBd3djZ0c1Z2dTeUQxSVhkRTBvdlhTVnpwbjN1TGdvNHIwaHNLa0QyMkZzLUpVUWh4RUNoRzV5ZE12cHRSNlVjR1ZLNkJUam9mMms2dWhibmFDQXFpMFhsck03SmVhVVotMVdVdENobGpkZHY2LXVNeUl6WUF5YW43bGxlYV9RQVJQSWM4NGFralU3NG5qa2JBUm9sWGZIWW5QMHBKanNZWXltai1IWldxSzc3R3pQX29ITDZ3Vy1POVRCellEdG90LVZXNXFZSW1zdGprNVMyakd1bDFheEhVbjk?oc=5","date":"2025-10-21","type":"trial","source":"BioSpace","summary":"Atom Therapeutics to Present Positive Data from Clinical Trials of Its Lead Novel Oral Drugs for Chronic Gout and Acute Gout Flares at ACR Convergence 2025 - BioSpace","headline":"Atom Therapeutics to Present Positive Data from Clinical Trials of Its Lead Novel Oral Drugs for Chronic Gout and Acute ","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiiAJBVV95cUxPNEx3eVdsSzFHVi1MSUxRenZ3TnlNbHBoSVhmVFBEYnJ3V3FIX1d5TlFFNnRqSnJWZTUxc1A1V3hyQnFIYUxfcXRxMHQ1b2x4bHpNWVRGTjNwci1SQ2FLZlVpQUowdHptTkVIQnpqdTNVWk95ck45aUdfRlBYdUo1d1ozQWxEajB5RGxoTWxnNkl5Y0VGZlBYYXMzeERSR1JVZ1B3dkVOREk2TXVNWWxMTFc4RW9iWkNwVWVIYWVrY0VCX2htU3NreHFGS3NvVFRBTk52TnZQTFFYVTlyYW1kaHRteWIyQTl1ZEpMc24yRkstUktTdUg5YzVXdFlVeldVMXFMY1NOZ1o?oc=5","date":"2025-09-16","type":"trial","source":"GlobeNewswire","summary":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight - GlobeNewswire","headline":"Gout Clinical Trial Pipeline Expands as 20+ Companies Driving Innovation in Gout Therapeutics | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxOTVI0UHNRQUE5QnpmT1k1WFp4aWx4NXRIUnI2cl9fTzVEbFRra3JpbHhhOUV1S2pqSUZwVFFnS3ZrQVdabXBhanh1blN6QUNBYmJLdmZfNTdjeGhnWDFPSDdNckRxX3hRWmw3c0lSaWU5NWdsY1h6TlVGZjY2WVNEUVRqRTRCM0xnbjl3UUliOG4tQnJiUXBYZEtrcW1FYnh5NUdQejNsZW8wZlc5b2lNUkxpLWxPZDhZWmFuUmFyazZCTzctV2pnVUhVcHBQNXNNOXA5ZUFha0FNU3ktcWVhZ1FsYzdxblVjMGc?oc=5","date":"2025-09-09","type":"trial","source":"BioSpace","summary":"Atom Therapeutics Announces Positive Topline Results of Lingdolinurad (ABP-671) in Phase 2b/3 Trial for Chronic Gout - BioSpace","headline":"Atom Therapeutics Announces Positive Topline Results of Lingdolinurad (ABP-671) in Phase 2b/3 Trial for Chronic Gout","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxQNGpRRC1mOEhEY2xVNWtEMnpoX1U5ZlVzU2JTNDRXVDJLM19vbWxSUkVnMWpjcHV0OFB5QjRDRm5xOWJHemtYUmYzSHV6UFR1NkxSUzNWQTVMcUVzQm9zM3d6TzM3Sm5TbWE1ci14aVVTaHE0eVJUM1pQZWM3b193bEw3dlBPS2NoQTU5b0wtS1B5QXpibi1FM19xZUphM245azdTMEJjZERTN3RrUHY2OHBvYjA?oc=5","date":"2025-09-08","type":"trial","source":"Fierce Biotech","summary":"Atom claims phase 3 win shows gout drug can beat competition in efficacy, safety - Fierce Biotech","headline":"Atom claims phase 3 win shows gout drug can beat competition in efficacy, safety","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgJBVV95cUxOdnpkVnR4Q1NKODl0Ny1ZWGNCZVYtMm5BRld6MlUwSTZsbk1BQzJCMm5qOVNhTjZ0WEltcWoxbkhkb3FjU1dnYU1WTnBBQ1RMS3BXR3VmN04zZGhzMDV1cWNDOC0zZVJtakNtQWE0aVJsR3pkN3owM3ZFemRtMjRQRjFmVkl3Ujh0d2ZFMF9zUVlmUml5YlE1bXBjZTB3WmJ4MU9OVnlKZDZHVjdsVGZ4dWI2cHQzb01WUDlXUl9iVjdlcGpJQ0tua1JqY2VSOGdKeTZBX3FaUG5TdjBFVUxIV2NFV2hnZXpTVWFZcGFfeXREaEVWaHI5eldCUmtUanBqZzhidkZSczRCLVUyYWdBTUVKZV9LVnVKRldMaHcycWpTLURIN293bldLV0ZrYk9YOGlYTGlkXy0zZkxNMEIyWDR3?oc=5","date":"2025-06-17","type":"pipeline","source":"PR Newswire","summary":"AtomVie Global Radiopharma and TerraPower Isotopes Announce Strategic Supply Agreement for Actinium-225 to Advance Radiopharmaceutical Development and Manufacturing - PR Newswire","headline":"AtomVie Global Radiopharma and TerraPower Isotopes Announce Strategic Supply Agreement for Actinium-225 to Advance Radio","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxPcmxiUm5Wd0dwZXUyLU54TUQ4Q2F2UWJuTmRtR3loME81NU1YYVJHYXpaejcxdWRPSmRMU1RSVHA1WDF6aHFFdURZM2VQZU9zQ0FmZTBKb19PbnlIa1JsTEFtYkwyWVViZUo4bTFKU05QM0tpQkZaZlNySUJSYjc0X2xvYkFibVFiMzZtenVvV0g5UFcydWdiVnRIeDJMT25hUjRGOVVZeDJQRmkzQUQzTy1fVWlSWEFnalg3NmVjbmJxTmlKV0M3dF82NW1fQVl4MF9Oc2FCSDJIN0xjTHFTaXpKc1BnaHZWSU9OeUdGOElrU0QxRHNtMXotZERkS0dNTGVoMTBmdTRJY0lud1ZaSkt0M2ZKSzIyS0lHUVFibWwyYjZRd2I4cW9OWGk3QQ?oc=5","date":"2025-05-22","type":"pipeline","source":"BioSpace","summary":"Atom Therapeutics Joins Gout Education Society on Gout Awareness Day, May 22, to Help Educate the Public on Risk Factors and Treatment Options for This Growing Disease - BioSpace","headline":"Atom Therapeutics Joins Gout Education Society on Gout Awareness Day, May 22, to Help Educate the Public on Risk Factors","sentiment":"neutral"}],"patents":[],"drugCount":5,"phaseCounts":{"phase_1":2,"phase_2":3},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}